Filing Details
VYNE Therapeutics Inc. (NASDAQ:VYNE) filed a Form 8-K with the Securities and Exchange Commission on July 14, 2026, disclosing a material event.
8k filedNASDAQ:VYNE
VYNE Therapeutics Inc. (VYNE) Reports Material Event to SEC
Filing Details VYNE Therapeutics Inc. (NASDAQ:VYNE) filed a Form 8-K with the Securities and Exchange Commission on July 14, 2026, disclosing a material event. Market Context VYNE…
Market Context
VYNE Therapeutics Inc.'s stock currently trades at $0.71 with a market capitalization of $6.8M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for VYNE Therapeutics Inc.'s stock.
All SEC filings for VYNE Therapeutics Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View VYNE Stock Page
Frequently Asked Questions
Where can I read VYNE's SEC filings?
Browse all filings on our VYNE SEC filings page.
What types of SEC filings does VYNE Therapeutics Inc. file?
Public companies like VYNE Therapeutics Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.